Sezione di Gastroenterologia ed Epatologia, Di.Bi.M.I.S., University of Palermo, Piazza delle Cliniche n.2, 90127 Palermo, Italy.
Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):219-30. doi: 10.1016/j.bpg.2011.02.012.
In the last years, several studies have been performed with the aim to evaluate the real impact of antiviral treatments on fibrosis progression in patients with chronic viral hepatitis. The main goal of therapy in patients with chronic hepatitis B is viral suppression. This outcome leads to an important improvement in both hepatic inflammation and fibrosis and reduces the HCC occurrence. An histological improvement has been largely demonstrated in patient treated with oral nucleoside and nucleotide analogs achieving the rate of 72% with entecavir and tenofovir. Similarly, in patients with chronic hepatitis C, sustained virologic response to interferon therapy is associated with regression of fibrosis and lower liver decompensation and HCC occurrence. In the next future further studies will assess the real impact of the new directly anti-viral agents on liver necroinflammation and fibrosis in chronic hepatitis C.
在过去的几年中，已经进行了多项研究，旨在评估抗病毒治疗对慢性病毒性肝炎患者纤维化进展的实际影响。慢性乙型肝炎患者治疗的主要目标是病毒抑制。这一结果不仅使肝炎症和纤维化得到重要改善，还降低了 HCC 的发生。口服核苷（酸）类似物治疗的患者已在很大程度上显示出组织学改善，恩替卡韦和替诺福韦的有效率分别达到 72%。同样，在慢性丙型肝炎患者中，干扰素治疗的持续病毒学应答与纤维化消退以及较低的肝失代偿和 HCC 发生相关。在未来的研究中，将进一步评估新型直接抗病毒药物对慢性丙型肝炎肝坏死炎症和纤维化的实际影响。
